440 related articles for article (PubMed ID: 15983290)
21. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Kuwajima I
Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
[No Abstract] [Full Text] [Related]
22. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
23. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Rahn KH
Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
[TBL] [Abstract][Full Text] [Related]
24. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
[TBL] [Abstract][Full Text] [Related]
25. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
Dewland TA; Soliman EZ; Davis BR; Magnani JW; Yamal JM; Piller LB; Haywood LJ; Alonso A; Albert CM; Marcus GM;
JAMA Intern Med; 2016 Aug; 176(8):1085-92. PubMed ID: 27367818
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
27. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
28. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Schillaci G; Verdecchia P
Ital Heart J Suppl; 2000 Sep; 1(9):1215-7. PubMed ID: 11140297
[No Abstract] [Full Text] [Related]
29. [Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Wepner U
MMW Fortschr Med; 2003 Jan; 145(1-2):10-2. PubMed ID: 12638431
[No Abstract] [Full Text] [Related]
30. [Treating hypertension is more important than the choice of agent; results from the largest clinical trial until now].
de Leeuw PW; Birkenhäger WH
Ned Tijdschr Geneeskd; 2003 Apr; 147(15):685-9. PubMed ID: 12722529
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
[TBL] [Abstract][Full Text] [Related]
32. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study.
Lewis CE; Grandits A; Flack J; McDonald R; Elmer PJ
Arch Intern Med; 1996 Feb; 156(4):377-85. PubMed ID: 8607723
[TBL] [Abstract][Full Text] [Related]
34. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
35. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
[TBL] [Abstract][Full Text] [Related]
36. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
Wu SC; Liu CP; Chiang HT; Lin SL
Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
[TBL] [Abstract][Full Text] [Related]
37. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
38. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
[TBL] [Abstract][Full Text] [Related]
39. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Siragy HM
Curr Hypertens Rep; 2003 Aug; 5(4):293-4. PubMed ID: 12844462
[No Abstract] [Full Text] [Related]
40. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
